Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightThe platelet-to-lymphocyte ratio was significantly higher in the rheumatic heart diseasegroup (110.86±46.67 vs. 90.07±21.56, p=0.01).Conclusion: The platelet-to-lymphocyte ratio was high, and the lymphocyte count was low in the rheumatic heartdisease group than the control group.
📌 3 Maddede Bu Makale
Abstract
Objectives: Rheumatic heart disease is a significant cause of morbidity and mortality in developed and undevelopedcountries. Rheumatic valve disease is the most long-term sequel in rheumatic heart disease, and the platelet to lymphocyteratio is a novel biomarker which is associated with poor clinical outcomes in various cardiovascular disorders.We evaluated the relationship between the platelet-to-lymphocyte ratio and chronic rheumatic heart disease.Methods: We analyzed 54 patients with rheumatic heart disease and 49 healthy subjects. All patients were evaluatedusing transthoracic echocardiography. In addition to echocardiographic and biochemical parameters, the platelet-tolymphocyteratio was compared between the groups.Results: There was no significant difference between the groups regarding ejection fraction, left atrium, left ventricularend diastolic diameter and left ventricle end systolic diameter in the echocardiographic assessment. Biochemical parameterswere similar between the groups regarding glucose, creatine, total cholesterol triglyceride, and low-densitylipoprotein. The lymphocyte count was significantly lower in the rheumatic heart disease group than the control group(2.46±0.70 vs. 2.64±0.53, p=0.01). The platelet-to-lymphocyte ratio was significantly higher in the rheumatic heart diseasegroup (110.86±46.67 vs. 90.07±21.56, p=0.01).Conclusion: The platelet-to-lymphocyte ratio was high, and the lymphocyte count was low in the rheumatic heartdisease group than the control group.